TL;DR
This paper introduces RT-LAMP-VF, a novel, rapid, and highly specific diagnostic assay for Middle East Respiratory Syndrome Coronavirus (MERS-CoV). It combines isothermal amplification with a visual readout strip, enabling detection within 35 minutes without specialized equipment, making it suitable for resource-limited settings.
What Problem Does This Paper Address?
Middle East Respiratory Syndrome Coronavirus (MERS-CoV) is a significant public health concern, causing severe respiratory illness with a high fatality rate. The lack of readily available, rapid, and accurate diagnostic tools hinders timely intervention, isolation, and outbreak control. Existing methods like RT-PCR, while sensitive, often require expensive equipment and trained personnel, limiting their use in many clinical and field settings. This paper aims to bridge this gap by developing a diagnostic assay that is both rapid and accessible.
Methods
The core innovation is the RT-LAMP-VF (Reverse Transcription Loop-Mediated Isothermal Amplification - Vertical Flow) assay. Here's a breakdown:
- RT-LAMP: This technique amplifies RNA into DNA and then amplifies that DNA isothermally (at a constant temperature), eliminating the need for thermal cycling machines. It uses a set of six primers that target conserved regions of the MERS-CoV N gene, enhancing amplification efficiency.
- Isothermal Amplification: Performed in a simple water bath at a constant temperature (optimized to 65°C for recombinant plasmids and 61°C for RNA transcripts).
- Vertical Flow Visualization Strip: This is the key to the "visual" aspect. After amplification, the products are detected using a strip similar to a pregnancy test.
- Labeling: Two loop primers (LF and LB) are labeled with FITC (fluorescein isothiocyanate) and biotin, respectively.
- Detection Mechanism: Biotinylated amplicons bind to streptavidin-coated gold nanoparticles, forming a complex. This complex is then captured by an anti-FITC antibody on the test line of the strip, resulting in a visible colored line.
- Primer Design: Six specific primers were designed for the MERS-CoV N gene using primer design software and synthesized.
- RNA Extraction: MERS-CoV RNA was extracted from infected cell cultures and synthesized using in vitro transcription.
Datasets
- MERS-CoV RNA: Synthesized RNA transcripts of the MERS-CoV N gene (based on the China GD01 strain, GenBank Accession No. KT006149) were used as the primary target for assay development and evaluation.
- Recombinant Plasmid: A pcDNA3.1(+) recombinant plasmid containing the MERS-CoV N gene was also used for initial optimization of reaction conditions.
- Cross-Reactivity Panel: Nucleic acids from multiple respiratory pathogens were used to assess the specificity of the assay. This included controls from the NATtrol™ RP Multimarker Controls kit (RP1 and RP2), which contained viruses like HKU-1, OC43, NL63, 229E, influenza A/B, rhinovirus, adenovirus, and parainfluenza. Additionally, SARS-related (SARSr)-CoV and HKU4 RNA were included.
- Clinical Sample Mimic: Total RNA from throat swabs of healthy individuals was used to evaluate the assay's performance when spiked with MERS-CoV RNA, mimicking clinical sample conditions.
Key Insights and Ideas
- Visual Detection is Key: The integration of a vertical flow strip transforms a molecular technique into a visually interpretable result, drastically reducing the need for specialized equipment and expertise.
- Optimized Primer Design: Using six primers (compared to the typical four or five in standard LAMP) significantly boosted amplification efficiency.
- Dual Labeling for Robust Signal: The FITC and biotin labeling strategy, combined with streptavidin-gold nanoparticles, creates a strong, visible signal on the test strip.
- Temperature Sensitivity: The optimal reaction temperature differed between using recombinant plasmids and synthesized RNA transcripts, highlighting the importance of template type in assay optimization. This was attributed to the need for reverse transcription and the stability of plasmid DNA.
- Clinical Sample Compatibility: The assay demonstrated that spiked MERS-CoV RNA in total throat swab RNA did not compromise sensitivity or specificity, suggesting its potential for direct use with clinical samples.
Key Results
- Rapid Detection: The RT-LAMP-VF assay completes detection in 30 minutes for the amplification step, with results visible on the strip within 5 minutes after amplification, for a total time of 35 minutes.
- High Sensitivity: The assay can detect as little as 2 × 10¹ copies/µl of synthesized RNA transcript and 1 × 10¹ copies/µl of MERS-CoV RNA.
- Excellent Specificity: The RT-LAMP-VF assay showed no cross-reactivity with a panel of other coronaviruses (SARSr-CoV, HKU4, HKU1, OC43, 229E) and other respiratory pathogens.
- Comparison to rRT-PCR: While real-time RT-PCR (rRT-PCR) achieved a slightly lower limit of detection (1 × 10⁰ copies/µl), the RT-LAMP-VF assay is significantly faster (35 min vs. ~2 hours for rRT-PCR) and requires no expensive equipment.
Limitations and Future Work
- Clinical Sample Availability: The authors note the difficulty in obtaining clinical MERS-CoV samples, especially from non-endemic regions like China, which limited direct testing on confirmed patient samples. They addressed this by using spiked throat swabs.
- Optimization Differences: The differing optimal temperatures for recombinant plasmids and synthesized RNA transcripts suggest that further fine-tuning might be beneficial depending on the exact template source.
- Future Work: The paper implicitly suggests that this assay is ready for adaptation to different laboratory settings due to its ease of use and portability. Further validation with a wider range of clinical samples and in diverse field conditions would be valuable.
Summary updated